FIELD: biotechnology.
SUBSTANCE: described is a method of treating an infectious disease in a subject, a method for modifying an immune response to an infectious agent in a subject and a method of activating T-cell responses to an infectious agent in a subject. Above methods are implemented with participation of an antibody or its antigen-binding part containing: Heavy chain CDR1 containing amino acids, having sequence given in SEQ ID NO: 15–21; CDR2 heavy chain containing amino acids having a sequence given in SEQ ID NO: 22–28; CDR3 heavy chain containing amino acids, having sequence given in SEQ ID NO: 29–35; CDR1 light chain containing amino acids having the sequence given in SEQ ID NO: 36–42; Light chain CDR2 containing amino acids, having sequence given in SEQ ID NO: 43–49; and light chain CDR3 containing amino acids having the sequence given in SEQ ID NO: 50–56.
EFFECT: invention extends the range of products for treating infectious diseases.
19 cl, 54 dwg, 7 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) | 2014 |
|
RU2723050C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| PD-1 BINDING ANTIBODIES AND METHODS OF THEIR USE | 2019 |
|
RU2812280C1 |
| ANTIBODIES TO PD-1 | 2015 |
|
RU2715628C2 |
| ANTIBODIES BINDING TO PD-1 AND THEIR APPLICATIONS | 2019 |
|
RU2773758C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| CD30XCD16 ANTIBODY COMBINATION FOR THERAPY WITH PD-1 ANTAGONIST | 2016 |
|
RU2761352C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
